Skip to main navigation Skip to search Skip to main content

Scaffold hopping of α-rubromycin enables direct access to FDA-approved cromoglicic acid as a SARS-CoV-2 MPro inhibitor

  • Hani A. Alhadrami
  • , Ahmed M. Sayed
  • , Heba Al-Khatabi
  • , Nabil A. Alhakamy
  • , Mostafa E. Rateb*
    • *Corresponding author for this work

    Research output: Contribution to journal › Article › peer-review

    17   Link opens in a new tab Citations (Scopus)
    47 Downloads (Pure)

    Fingerprint

    Dive into the research topics of 'Scaffold hopping of α-rubromycin enables direct access to FDA-approved cromoglicic acid as a SARS-CoV-2 MPro inhibitor'. Together they form a unique fingerprint.
    Sort by

    Keyphrases

    Medicine and Dentistry

    Pharmacology, Toxicology and Pharmaceutical Science